Drug Search Results
More Filters [+]

Levomepromazine

Alternative Names: levomepromazine, levoprome
Latest Update: 2021-09-09
Latest Update Note: Clinical Trial Update

Product Description

Levomepromazine is a neuroleptic agent (an antipsychotic) which is commonly used to relieve nausea and vomiting in palliative care settings.  (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481825/)

Mechanisms of Action: DR Antagonist,5-HT Antagonist,mAChR Antagonist,ADR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Greece | Hungary | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Ukraine | United Kingdom | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Levomepromazine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title